Demant A/S

CPSE:DEMANT Stock Report

Market Cap: DKK 46.3b

Demant Valuation

Is DEMANT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DEMANT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

DKK 669.61
Fair Value
67.5% undervalued intrinsic discount
17
Number of Analysts

Below Fair Value: DEMANT (DKK217.4) is trading below our estimate of fair value (DKK669.61)

Significantly Below Fair Value: DEMANT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DEMANT?

Key metric: As DEMANT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DEMANT. This is calculated by dividing DEMANT's market cap by their current earnings.
What is DEMANT's PE Ratio?
PE Ratio17.4x
EarningsDKK 2.67b
Market CapDKK 46.31b

Price to Earnings Ratio vs Peers

How does DEMANT's PE Ratio compare to its peers?

The above table shows the PE ratio for DEMANT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.1x
AMBU B Ambu
38.6x20.10%DKK 23.5b
EMBLA Embla Medical hf
28.9x14.43%DKK 14.4b
COLO B Coloplast
35.9x15.44%DKK 130.5b
6869 Sysmex
20.9x12.29%JP¥971.9b
DEMANT Demant
17.4x11.83%DKK 46.3b

Price-To-Earnings vs Peers: DEMANT is good value based on its Price-To-Earnings Ratio (17.4x) compared to the peer average (31x).

Price to Earnings Ratio vs Industry

How does DEMANT's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
DEMANT 17.4xIndustry Avg. 27.9xNo. of Companies15PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DEMANT is good value based on its Price-To-Earnings Ratio (17.4x) compared to the European Medical Equipment industry average (27.8x).

Price to Earnings Ratio vs Fair Ratio

What is DEMANT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DEMANT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.4x
Fair PE Ratio31.4x

Price-To-Earnings vs Fair Ratio: DEMANT is good value based on its Price-To-Earnings Ratio (17.4x) compared to the estimated Fair Price-To-Earnings Ratio (31.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DEMANT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 217.40
DKK 275.18
+26.58%
11.04%DKK 316.00DKK 233.00n/a17
Nov ’26DKK 215.40
DKK 283.69
+31.70%
10.06%DKK 330.00DKK 240.00n/a16
Oct ’26DKK 226.00
DKK 293.13
+29.70%
9.87%DKK 335.00DKK 245.00n/a16
Sep ’26DKK 246.00
DKK 291.50
+18.50%
9.72%DKK 335.00DKK 245.00n/a16
Aug ’26DKK 244.80
DKK 294.94
+20.48%
9.85%DKK 338.00DKK 250.00n/a16
Jul ’26DKK 266.00
DKK 295.56
+11.11%
9.72%DKK 338.00DKK 250.00n/a16
Jun ’26DKK 257.00
DKK 281.83
+9.66%
10.15%DKK 320.00DKK 220.00n/a18
May ’26DKK 236.60
DKK 291.72
+23.30%
11.06%DKK 350.00DKK 240.00n/a18
Apr ’26DKK 231.20
DKK 299.83
+29.69%
11.40%DKK 360.00DKK 240.00n/a18
Mar ’26DKK 258.80
DKK 301.53
+16.51%
11.42%DKK 360.00DKK 240.00n/a17
Feb ’26DKK 290.00
DKK 303.00
+4.48%
10.22%DKK 360.00DKK 250.00n/a17
Jan ’26DKK 264.20
DKK 296.82
+12.35%
10.37%DKK 350.00DKK 245.00n/a17
Dec ’25DKK 269.20
DKK 296.41
+10.11%
10.50%DKK 350.00DKK 245.00n/a17
Nov ’25DKK 260.60
DKK 302.41
+16.04%
10.44%DKK 360.00DKK 250.00DKK 215.4017
Oct ’25DKK 261.20
DKK 301.31
+15.36%
11.08%DKK 370.00DKK 250.00DKK 226.0016
Sep ’25DKK 285.60
DKK 303.81
+6.38%
11.64%DKK 370.00DKK 230.00DKK 246.0016
Aug ’25DKK 263.00
DKK 314.94
+19.75%
13.85%DKK 381.00DKK 230.00DKK 244.8016
Jul ’25DKK 301.80
DKK 336.69
+11.56%
14.11%DKK 400.00DKK 268.00DKK 266.0016
Jun ’25DKK 329.00
DKK 337.31
+2.53%
14.27%DKK 400.00DKK 268.00DKK 257.0016
May ’25DKK 321.00
DKK 334.75
+4.28%
15.47%DKK 400.00DKK 240.00DKK 236.6016
Apr ’25DKK 343.00
DKK 339.47
-1.03%
15.81%DKK 405.00DKK 240.00DKK 231.2017
Mar ’25DKK 353.30
DKK 336.53
-4.75%
15.14%DKK 400.00DKK 240.00DKK 258.8017
Feb ’25DKK 317.60
DKK 298.71
-5.95%
13.52%DKK 355.00DKK 235.00DKK 290.0017
Jan ’25DKK 296.00
DKK 288.71
-2.46%
15.05%DKK 350.00DKK 185.00DKK 264.2017
Dec ’24DKK 282.30
DKK 286.76
+1.58%
13.40%DKK 335.00DKK 185.00DKK 269.2017
Nov ’24DKK 272.10
DKK 287.69
+5.73%
15.40%DKK 340.00DKK 185.00DKK 260.6016
DKK 275.18
Fair Value
21.0% undervalued intrinsic discount
17
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/24 12:15
End of Day Share Price 2025/11/24 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Demant A/S is covered by 40 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Edward Ridley-DayBarclays
Hassan Al-WakeelBarclays